{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:25:57Z","timestamp":1790699157059,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2329-5","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T11:18:57Z","timestamp":1490613537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza"],"prefix":"10.1186","volume":"17","author":[{"given":"M. D","family":"Heath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. J.","family":"Swan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. J.","family":"Silman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Prevosto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. E.","family":"Gooch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,27]]},"reference":[{"key":"2329_CR1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1056\/NEJMra0904322","volume":"361","author":"M Shanta","year":"2009","unstructured":"Shanta M, Zimmer MD, Burke DS. Historical Perspective \u2014 Emergence of Influenza A (H1N1) Viruses. NEJM. 2009;361:279\u201385.","journal-title":"NEJM"},{"key":"2329_CR2","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1073\/pnas.73.9.3045","volume":"73","author":"D McGeogh","year":"1976","unstructured":"McGeogh D, Fellner P, Newton C. Influenza virus genome consists of eight distinct RNA species. Proc Natl Acad Sci U S A. 1976;73:3045\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2329_CR3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev.med.51.1.407","volume":"51","author":"NJ Cox","year":"2000","unstructured":"Cox NJ, Subbarao K. Global epidemiology of influenza: Past and present. Annu Rev Med. 2000;51:407\u201321.","journal-title":"Annu Rev Med"},{"key":"2329_CR4","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s11262-013-0980-5","volume":"47","author":"I Khandaker","year":"2013","unstructured":"Khandaker I, Suzuki A, Kamigaki T, Tohma K, Odagiri T, Okada T, et al. Molecular evolution of the hemagglutinin and neuraminidase genes of pandemic (H1N1) 2009 influenza viruses in Sendai, Japan, during 2009-2011. Virus Genes. 2013;47:456\u201366.","journal-title":"Virus Genes"},{"key":"2329_CR5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nature08157","volume":"459","author":"G Neumann","year":"2009","unstructured":"Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009;459:931\u20138.","journal-title":"Nature"},{"key":"2329_CR6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/4641112a","volume":"464","author":"D Butler","year":"2010","unstructured":"Butler D. Portrait of a year-old pandemic. Nature. 2010;464:1112\u20133.","journal-title":"Nature"},{"key":"2329_CR7","doi-asserted-by":"crossref","unstructured":"Gilca R, Skowronski DM, Douville-Fradet M, et al. Mid-season estimates of influenza vaccine effectiveness against influenza A (H3N2) hospitalization in the elderly in Quebec, Canada, January 2015. PLoS One. 2015;10(7):e0132195.","DOI":"10.1371\/journal.pone.0132195"},{"key":"2329_CR8","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1016\/j.vaccine.2007.07.027","volume":"25","author":"F Carrat","year":"2007","unstructured":"Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine. 2007;25:6852\u201362.","journal-title":"Vaccine"},{"key":"2329_CR9","first-page":"61","volume":"34","author":"BJ Cowling","year":"2016","unstructured":"Cowling BJ, Feng S, Finelli L, Steffens A, Fowlkes A. Assessment of influenza vaccine effectiveness in a sentinel surveillance network 2010\u201313. United States Vaccine. 2016;34:61\u20136.","journal-title":"United States Vaccine"},{"key":"2329_CR10","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1016\/j.vaccine.2012.03.043","volume":"30","author":"S Rockman","year":"2012","unstructured":"Rockman S, Middleton DJ, Pearse MJ, Barr IG, Lowther S, Brown LE. Control of pandemic (H1N1) 2009 influenza virus infection of ferret lungs by non-adjuvant-containing pandemic and seasonal vaccines. Vaccine. 2012;30:3618\u201323.","journal-title":"Vaccine"},{"key":"2329_CR11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1099\/vir.0.058636-0","volume":"95","author":"S-J Park","year":"2014","unstructured":"Park S-J, Kim E-H, Pascua PNQ, Kwon H-I, Lim G-J, Decano A, et al. Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models. J Gen Virol. 2014;95:793\u20138.","journal-title":"J Gen Virol"},{"key":"2329_CR12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1086\/656188","volume":"202","author":"KL Laurie","year":"2010","unstructured":"Laurie KL, Carolan LA, Middleton D, Lowther S, Kelso A, Barr IG. Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis. 2010;202:1011\u201320.","journal-title":"J Infect Dis"},{"key":"2329_CR13","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.vaccine.2010.12.125","volume":"29","author":"B Baras","year":"2011","unstructured":"Baras B, de Waal L, Stittelaar KJ, Jacob V, Giannini S, Kroeze EJBV, et al. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in na\u00efve ferrets. Vaccine. 2011;29:2120\u20136.","journal-title":"Vaccine"},{"key":"2329_CR14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nri3694","volume":"14","author":"EG Gregorio","year":"2014","unstructured":"Gregorio EG, Rappuoli R. From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nat Rev Immunol. 2014;14:505\u201314.","journal-title":"Nat Rev Immunol"},{"key":"2329_CR15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","volume":"4","author":"S Awate","year":"2013","unstructured":"Awate S, Babiuk LA, Mutwiri G. Mechanism of action of adjuvants. Front Immunol. 2013;4:114.","journal-title":"Front Immunol"},{"key":"2329_CR16","doi-asserted-by":"crossref","unstructured":"Chia M-Y, Hu AY-C, Tseng Y-F, Weng T-C, Lai C-C, Lin J-Y, et al. Evaluation of MDCK Cell-Derived Influenza H7N9 Vaccine Candidates in Ferrets. PLoS One. 2015;10","DOI":"10.1371\/journal.pone.0120793"},{"key":"2329_CR17","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1016\/j.vaccine.2015.09.065","volume":"33","author":"S Pillet","year":"2015","unstructured":"Pillet S, Racine T, Nfon C, Di Lenardo TZ, Babiuk S, Ward BJ, et al. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets. Vaccine. 2015;33:6282\u20139.","journal-title":"Vaccine"},{"key":"2329_CR18","doi-asserted-by":"crossref","first-page":"17585","DOI":"10.1073\/pnas.1207308109","volume":"109","author":"CH Clegg","year":"2012","unstructured":"Clegg CH, Roque R, Van Hoeven N, Perrone L, Baldwin SL, Rininger JA, et al. Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci U S A. 2012;109:17585\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2329_CR19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jat.869","volume":"22","author":"P Baldrick","year":"2002","unstructured":"Baldrick P, Richardson D, Wheeler AW. Review of L-tyrosine confirming its safe human use as an adjuvant. J Appl Toxicol. 2002;22:333\u201344.","journal-title":"J Appl Toxicol"},{"key":"2329_CR20","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.4161\/hv.24631","volume":"9","author":"M Rosewich","year":"2013","unstructured":"Rosewich M, Lee D, Zielen S. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis. Hum Vaccin Immunother. 2013;9:1523\u201331.","journal-title":"Hum Vaccin Immunother."},{"key":"2329_CR21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000233157","volume":"69","author":"AW Wheeler","year":"1982","unstructured":"Wheeler AW, Moran DM, Robins BE, Driscoll A. L-Tyrosine as an Immunological Adjuvant. Int Arch Allergy Immunol. 1982;69:113\u20139.","journal-title":"Int Arch Allergy Immunol"},{"key":"2329_CR22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jinorgbio.2015.08.007","volume":"152","author":"AJ Bell","year":"2015","unstructured":"Bell AJ, Heath MD, Hewings SJ, Skinner MA. The adsorption of allergoids and 3-O-desacyl-4\u2032-monophosphoryl lipid A (MPL\u00ae) to microcrystalline tyrosine (MCT) in formulations for use in allergy immunotherapy. J Inorg Biochem. 2015;152:147\u201353.","journal-title":"J Inorg Biochem"},{"key":"2329_CR23","doi-asserted-by":"crossref","unstructured":"DuBuske LM1, Frew AJ, Horak F, Keith PK, Corrigan CJ, Aberer W, Holdich T, von Weikersthal-Drachenberg KJ.Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc. 2011;32(3):239\u201347.\u00a0","DOI":"10.2500\/aap.2011.32.3453"},{"key":"2329_CR24","unstructured":"[ http:\/\/otp.investis.com\/clients\/uk\/allergy_therapeutics\/rns\/regulatory-story.aspx?newsid=720112&cid=1045 ]. Accessed 29 July 2016."},{"key":"2329_CR25","doi-asserted-by":"crossref","unstructured":"Marriott AC, Dove BK, Whittaker CJ, Bruce C, Ryan KA, Bean TJ, Rayner E, Pearson G, Taylor I, Dowall S, Plank J, Newman E, Barclay WS, Dimmock NJ, Easton AJ, Hallis B, Silman NJ, Carroll MW. Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir. PLoS One. 2014;9","DOI":"10.1371\/journal.pone.0094090"},{"key":"2329_CR26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem. 1976;72:248\u201354.","journal-title":"Anal Biochem"},{"key":"2329_CR27","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2014.01.077","volume":"32","author":"R Scherliess","year":"2014","unstructured":"Scherliess R, Ajmera A, Dennis M, Carroll MW, Altrichter J, Silman NJ, Scholz M, Kemter K, Marriott AC. Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates. Vaccine. 2014;32:2231\u201340.","journal-title":"Vaccine"},{"key":"2329_CR28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1128\/IAI.13.2.417-424.1976","volume":"13","author":"PA Small","year":"1976","unstructured":"Small PA, Waldman RH, Bruno JC, Gifford GE. Influenza infection in ferrets: role of serum antibody in protection and recovery. Infect Immun. 1976;13:417\u201324.","journal-title":"Infect Immun"},{"key":"2329_CR29","first-page":"63","volume":"115","author":"JC de Jong","year":"2003","unstructured":"de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2003;115:63\u201373.","journal-title":"Dev Biol (Basel)"},{"key":"2329_CR30","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1242\/dmm.007823","volume":"4","author":"JA Belser","year":"2011","unstructured":"Belser JA, Katz JM, Tumpey TM. The ferret as a model organism to study influenza A virus infection. Dis Model Mech. 2011;4:575\u20139.","journal-title":"Dis Model Mech"},{"key":"2329_CR31","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1586\/14760584.7.6.783","volume":"7","author":"JW Laan van der","year":"2008","unstructured":"van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, Oxford J. Animal models in influenza vaccine testing. Expert Rev. Vaccines. 2008;7:783\u201393.","journal-title":"Expert Rev. Vaccines"},{"key":"2329_CR32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","volume":"9","author":"P Marrack","year":"2009","unstructured":"Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9:287\u201393.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2329_CR33","first-page":"1","volume":"3","author":"H Khong","year":"2015","unstructured":"Khong H, Sharma M, Dai Z, Singh M, Hailemichael Y, Overwijk W. L-tyrosine is a promising cancer vaccine adjuvant. J ImmunoTherapy of Cancer. 2015;3(2):1\u20131.","journal-title":"J ImmunoTherapy of Cancer"},{"key":"2329_CR34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jps.22284","volume":"100","author":"T Clapp","year":"2011","unstructured":"Clapp T, Siebert P, Chen D, Jones BL. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. J Pharm Sci. 2011;100:388\u2013401.","journal-title":"J Pharm Sci"},{"key":"2329_CR35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.0818-9641.2004.01286.x","volume":"82","author":"EB Lindblad","year":"2004","unstructured":"Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol. 2004;82:497\u2013505.","journal-title":"Immunol Cell Biol"},{"key":"2329_CR36","unstructured":"WHO Expert Committee on Biological Standardization Sixty-third report. Recommendations to assure the quality, safety and efficacy of tetanus vaccines (adsorbed) Replacement of Annex 2 of WHO Technical Report Series, No. 800, and Annex 5 of WHO Technical Report Series, No. 927."},{"key":"2329_CR37","doi-asserted-by":"crossref","unstructured":"O\u2019Hagan DT, Fox CB. New generation adjuvants \u2013 From empiricism to rational design. Vaccine. 2015:B14\u201320.","DOI":"10.1016\/j.vaccine.2015.01.088"},{"key":"2329_CR38","doi-asserted-by":"crossref","first-page":"e49394","DOI":"10.1371\/journal.pone.0049394","volume":"7","author":"NJ Dimmock","year":"2012","unstructured":"Dimmock NJ, Dove BK, Scott PD, Meng B, Taylor I, Cheung L, Hallis B, Marriott AC, Carroll M, Easton AJ. Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established. PLoS One. 2012;7:e49394.","journal-title":"PLoS One"},{"key":"2329_CR39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.antiviral.2012.09.017","volume":"96","author":"NJ Dimmock","year":"2012","unstructured":"Dimmock NJ, Dove BK, Meng B, Scott PD, Taylor I, Cheung L, Hallis B, Marriott AC, Carroll MW, Easton AJ. Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir. Antivir Res. 2012;96:376\u201385.","journal-title":"Antivir Res"},{"key":"2329_CR40","first-page":"168","volume":"53","author":"CW Potter","year":"1972","unstructured":"Potter CW, Shore SL, McLaren C, Stuart-Harris C. Immunity to influenza in ferrets. II. Influence of adjuvants on immunization. Br J Exp Pathol. 1972;53:168\u201379.","journal-title":"Br J Exp Pathol"},{"key":"2329_CR41","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0264-410X(00)00499-0","volume":"21","author":"A Podda","year":"2001","unstructured":"Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001;21:2673\u201380.","journal-title":"Vaccine"},{"issue":"29","key":"2329_CR42","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","volume":"30","author":"DT O'Hagan","year":"2012","unstructured":"O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine. 2012;30(29):4341\u20138.","journal-title":"Vaccine"},{"issue":"7","key":"2329_CR43","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.vaccine.2009.12.014","volume":"28","author":"F Roman","year":"2010","unstructured":"Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine. 2010;28(7):1740\u20135.","journal-title":"Vaccine"},{"key":"2329_CR44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-065X.1997.tb01009.x","volume":"159","author":"W Gerhard","year":"1997","unstructured":"Gerhard W, Mozdzanowska K, Furchner M, Washko G, Maiese K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev. 1997;159:95\u2013103.","journal-title":"Immunol Rev"},{"key":"2329_CR45","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.4049\/jimmunol.1002090","volume":"186","author":"EE Waffarn","year":"2011","unstructured":"Waffarn EE, Baumgarth N. Protective B cell responses to flu\u2014no fluke! J Immunol. 2011;186:3823\u20139.","journal-title":"J Immunol"},{"issue":"2","key":"2329_CR46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000049504","volume":"126","author":"AW Wheeler","year":"2001","unstructured":"Wheeler AW, Marshall JS, Ulrich JT. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol. 2001;126(2):135\u20139.","journal-title":"Int Arch Allergy Immunol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2329-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T11:49:18Z","timestamp":1601812158000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2329-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,27]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2329"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2329-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,27]]},"article-number":"232"}}